Autolus Therapeutics plc ADR (NASDAQ: AUTL) on Friday, plunged -3.78% from the previous trading day, before settling in for the closing price of $1.85. Within the past 52 weeks, AUTL’s price has moved between $1.11 and $5.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 21.35% over the last five years. The company achieved an average annual earnings per share of -0.56%. With a float of $240.33 million, this company’s outstanding shares have now reached $266.14 million.
The firm has a total of 647 workers. Let’s measure their productivity. In terms of profitability, gross margin is -272.13%, operating margin of -2973.1%, and the pretax margin is -2600.97%.
Autolus Therapeutics plc ADR (AUTL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 53.35%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.31 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.22) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.29% during the next five years compared to 21.35% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Autolus Therapeutics plc ADR (AUTL) is currently performing well based on its current performance indicators. A quick ratio of 8.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Analysing the last 5-days average volume posted by the [Autolus Therapeutics plc ADR, AUTL], we can find that recorded value of 5.15 million was better than the volume posted last year of 1.87 million. As of the previous 9 days, the stock’s Stochastic %D was 6.93%.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 42.32%, which indicates a significant increase from 13.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1710 in the past 14 days, which was higher than the 0.1419 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.3205, while its 200-day Moving Average is $2.1930. Now, the first resistance to watch is $1.8900. This is followed by the second major resistance level at $2.0000. The third major resistance level sits at $2.1200. If the price goes on to break the first support level at $1.6600, it is likely to go to the next support level at $1.5400. Should the price break the second support level, the third support level stands at $1.4300.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
Market capitalization of the company is 473.73 million based on 266,141K outstanding shares. Right now, sales total 10,120 K and income totals -220,660 K. The company made 8,980 K in profit during its latest quarter, and -70,160 K in sales during its previous quarter.
